Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedLocations are reorganized under a new consolidated 'Locations' section, adding Ontario and Quebec sites and removing the previous separate state/location blocks.SummaryDifference1%

- Check21 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedOnly the revision tag changed from v3.2.0 to v3.3.2; no core content appears to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check44 days agoChange DetectedA government funding/operating-status notice was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check58 days agoChange DetectedNo substantive updates to the study details were observed; differences appear limited to formatting or visual layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check87 days agoChange DetectedUpdated version to v3.2.0 and added a government operating-status notice; removed the previous v3.1.0 reference.SummaryDifference3%

- Check94 days agoChange DetectedPage updated to v3.1.0; removed the Ovarian cancer resource and old v3.0.2 reference.SummaryDifference0.3%

Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.